Sodium Sulfacetamide, Sulfur
Sodium Sulfacetamide, Sulfur is an FDA drug label for the active ingredient SULFACETAMIDE SODIUM, SULFUR manufactured by BioComp Pharma, Inc. administered by TOPICAL. This page reproduces the FDA-approved indications and usage, dosage, contraindications, warnings, and adverse reactions exactly as published in the drug label. Data source: openFDA (U.S. FDA), label effective 20230824.
Generic: SULFACETAMIDE SODIUM, SULFUR
Manufacturer: BioComp Pharma, Inc.
Product Type: HUMAN PRESCRIPTION DRUG
Route: TOPICAL
Dosage Form:
NDC: 44523-550
Application:
Effective: 20230824
Indications & Usage
INDICATIONS: This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.
Dosage & Administration
DOSAGE AND ADMINISTRATION: Shake well before using. Wash affected areas once or twice daily, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10 to 20 seconds, working into a full lather, rinse thoroughly and pat dry. If skin dryness occurs, it may be controlled by rinsing product off sooner or using less frequently.
Contraindications
CONTRAINDICATIONS: This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. This product is not to be used by patients with kidney disease.
Warnings
WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF THE REACH OF CHILDREN.
Adverse Reactions
ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).
More from same ingredient
Plexion
Eckson Labs, LLC
Plexion
Eckson Labs LLC
Plexion
Eckson Labs LLC
SULFACETAMIDE SODIUM, SULFUR
KMM Pharmaceuticals, LLC
SULFACETAMIDE SODIUM, SULFUR
KMM Pharmaceuticals, LLC
Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser
KMM Pharmaceuticals, LLC